Emerging therapeutic targets in esophageal adenocarcinoma.

Oncotarget · 2016 · PMC5217045 · PMID 27102294

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

Despite these large randomized trials, the overall benefits of these two biological agents are marginally significant with survival difference of merely 2-3 months.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.